Indonesia Secures Drug Supply with Remdesivir, Favipiravir Patents


Indonesia President Joko "Jokowi" Widodo issued regulations to fulfill the availability of  COVID-19 drugs, Remdesivir and Favipiravir, as stipulated in the Presidential Regulation (Perpres) No. 100/2021 and 101/2021 on patents for Remdesivir and Favipirapir. "The government needs to establish a policy on access to drugs that are currently still protected by patents," reads the second consideration of the regulation, released on November 10.

The regulation stipulates that the government patents on Remdesivir and Favipiravir will run for three years with possible extension if the COVID-19 pandemic has not ended. The Health Minister will appoint the pharmaceutical industry as the patents executor. The appointed pharmaceutical manufacturer will carry out the duties of implementing the Favirapir and Remdesivir patents on a limited basis.

Start your free trial.

If you would like to get a 30-day free unlimited access to all of our insights, please click “Start free trial” button below. If you already have an account, please login.

What do subscribers receive?

As a subscriber, you’ll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Enjoy a 30-day free trial, on us. Feel free to contact us with any additional questions you have.